Nivi published in JGO

R2 Nivi Arora has had a busy few weeks. She recently published this JAMA Internal Medicine Teachable moment recommending against broad upfront ANA sub-serology testing, especially without a positive ANA.

She now has a first-author review paper, titled ”Biological agents in gastrointestinal cancers: adverse effects and their management” published in the Journal of Gastrointestinal Oncology.


Take home points:

Anti VEGF agents—bevacizumab, aflibercept and ramucirumab:  renal (proteinuria) and vascular complications (hypertension, thrombosis, GI perforations)

Anti EGFR agents – cetuximab and panitumumab:  dermatological toxicity (acne, papulopustular lesions) and hypomagnesemia

Congratulations Nivi !!

— Chiefs